|
1.
Share Success: Letters From Readers
***************************************************
Letter
I: From Alain D.
Received
at orderprocessing@ezorbonline.com on Tuesday, June 24, 2014 8:02 PM
(Unedited)
Glad to know my order has been shipped! It is the third time I reorder Marvlix( I am curious about the name Marvlix though I know the product is Cordyceps sinensis.)
If you had a Canadian distributor I believe I could save on shipping? I have noticed a huge improvement with my respiratory problem.
Thank you,
Alain D.
PS/ I reorder this time due to a bad chest cold and cough.
Letter
II: From Valerie F.
Received
at Testimonial
Submit Form on Wednesday, April 09, 2014 at 00:42:07
(Unedited)
Hi, my name is Valerie F. and I have been taking EZorb for about eight years.
I had severe fibromyalgia symptoms. My life had come to a standstill because I could not function. I was in such severe pain, I was so tired all the time and I had so much brain fog that I felt I could not even speak properly.
My sister told me about EZorb. She was using it for heel spurs and it worked really well
for her, so I decided to try it.
Believe me, it was one of the best decisions I have ever made. I took it exactly as the instructions said. In two weeks I started noticing a decrease in tiredness. In a month the
nausea was getting better. In two months I was feeling better everywhere.
And by three months, which is the time given for this product to work, I had my life back. I am forty five now and I have a very active lifestyle with lots of energy for my family and my job.
Thank you so much for this amazing product.
Letter
III: From Mickie
Received
at Testimonial
Submit Form on
Friday, February 28, 2014 at 22:59:54
(Unedited)
My husbands knee spurs are gone after taking your product. He went for his heel test for osteoporosis. He was told he passed a few years ago, they told him after this test he was in line for osteoporosis. That's why he bought EZorb.
***************************************************
From
the Desk of EZorb Newsletter Editor:
This
newsletter is now read by over 70,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess@elixirindustry.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public.
2.
Research News: Hypertension Control May Protect Kidneys in Diabetics
Elevated blood pressure (BP) is associated with an increased risk of renal damage in patients with Type 2 diabetes, especially if they have poor glycaemic control, study findings suggest.
"Our results support strong consideration for treatment of higher levels of systolic hypertension for renal protection", say study author Robert Anderson (Veterans Affairs Medical Center, Omaha, Nebraska, USA) and team.
Their findings emerge from a post-hoc analysis of data from the Veterans Affairs Diabetes Trial (VADT), including 1374 patients with complete albumin-to-creatinine ratio (ACR) data and 1649 with complete estimated glomerular filtration rate (eGFR) data. The patients were aged an average of 60.4 years.
During up to 7 years of follow-up, the likelihood of patients experiencing a deterioration in ACR rose with increasing on-study systolic (S)BP but not diastolic (D)BP. Relative to those with an on-study SBP between 105 and 129 mmHg, patients with SBP of 130 to 139 mmHg had a 1.88-fold increased risk of a deterioration in ACR and those with SBP of 140 mmHg or more had a 2.52-fold increased risk.
Patients' BP was not significantly associated with worsening eGFR; however, there was an interaction with glycated haemoglobin level such that there was an increased risk of worsening eGFR in patients with systolic hypertension and poor glycaemic control.
Pulse pressure (PP) was also associated with renal outcomes, with the likelihood of ACR worsening significantly increasing at a PP of 60 mmHg or higher, at a 2.38-fold increase relative to a PP of 40-49 mmHg. By contrast, the risk was reduced by a significant 64% in patients with PP lower than 40 mmHg.
Because there was no sign of an association between DBP and renal outcomes, the researchers attribute the effect of PP on renal outcomes to its association with SBP.
"Given the age of our study population, the increased PP may represent arterial stiffening with increased SBP without elevation of the DBP as a major contributor to this finding", they comment in Diabetes Care.
When analysed as continuous variables, on-study SBP and PP, but not DBP, were significantly associated with both ACR and eGFR worsening. Notably, baseline PP was also associated with eGFR worsening.
The team concludes that the risk of renal damage in diabetes patients emerges at a SBP of between 130 and 139 mmHg, but a SBP of 140 mmHg reflects a "more critical" level when eGFR may also be affected.
Original research was published in Bipolar Disord 2013; Advance online publication.
3.
Useful Links
Frequently
Asked Questions & Answers
EZorb
Clinical Studies
Marvlix
Benefits
Order
Now
4.
Calcium
Absorption Test
EZorb
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test@elixirindustry.com
for a copy of the instructions.
5.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix. |
